Stockwinners Market Radar for December 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
GOOG... | Hot Stocks20:05 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Novo Nordisk (NVO) announced that all regulatory closing conditions relating to the review of its pending acquisition of Catalent (CTLT), including expiry of the timing agreement in the U.S., have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings. Novo Nordisk now expects the acquisition to be completed in the coming days. 2. Apple (AAPL) is preparing a series of major design and format changes to its lineup of iPhones and potentially other products, a bid to revive growth after years of offering largely incremental upgrades, The Wall Street Journal's Aaron Tilley and Yang Jie report. Starting next year, Apple plans to introduce an iPhone that will be thinner than the approximately 8-millimeter profile of current models, said people familiar with the company's plans. The model is intended to be cheaper than Pro models, with a simplified camera system to reduce costs. 3. The Magnificent Seven stocks--Apple, Alphabet (GOOGL), Amazon (AMZN), Meta (META), Microsoft (MSFT), Nvidia (NVDA) and Tesla (TSLA)--thoroughly dominated the stock market in 2024, but they might not be the only place to invest in 2025, Andrew Bary writes in this week's edition of Barron's. The list of Barron's 10 favorite stocks for 2025 reflects an expectation that opportunities exist outside the Magnificent Seven, while overall stock market returns could be more muted after back-to-back gains of more than 25% for the S&P 500 index. It reflects a bet that value-oriented investing isn't completely dead. The list includes Alphabet, ASML Holding (ASML), Alibaba (BABA), Uber Technologies (UBER), Berkshire Hathaway (BRK.B), Citigroup (C), Everest Group (EG), Moderna (MRNA), SLB (SLB), and LVMH (LVMUY). 4. Walt Disney's (DIS) sequel "Moana 2" won the weekend at the North American box office with $26.6M for a domestic cume of $337.5M, as it crossed the $700M mark globally. Meanwhile, Sony's (SONY) comic book movie "Kraven the Hunter" disappointed with only $11M in its debut, the worst start ever for a Sony-produced Marvel title. 5. Exxon Mobil (XOM) saw a positive mention in this week's edition of Barron's.
|
PHAR | Hot Stocks16:34 EST Pharming announces public cash offer to shareholders of Abliva AB - Pharming announced a recommended public cash offer to the shareholders of Abliva AB to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately $66.1M. The Board of Directors of Abliva unanimously recommends the shareholders of Abliva to accept the Offer. The Board of Directors of Abliva has obtained a fairness opinion from PwC, according to which, based on the assumptions and reservations stated in the opinion, the Offer is fair to Abliva's shareholders from a financial perspective. Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and Pharming expects to obtain such approvals prior to the end of the acceptance period. Pharming Group N.V. has cash on hand to finance the Offer in full. The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025.
|